Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 10, 2025 08:00 ET
|
Alumis Inc.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
March 08, 2025 09:00 ET
|
Alumis Inc.
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025 09:01 ET
|
Alumis Inc.
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025 09:08 ET
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025 16:45 ET
|
Alumis Inc.
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025 16:15 ET
|
Alumis Inc.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis Strengthens Leadership Team with Key Appointments
January 28, 2025 08:00 ET
|
Alumis Inc.
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024 08:00 ET
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 03, 2024 16:10 ET
|
Amarna Therapeutics
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development Leiden, The Netherlands, 3 December 2024 - Amarna Therapeutics, (“Amarna” or “the Company”), a...
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
November 04, 2024 08:00 ET
|
Alumis Inc.
Alumis CEO will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tues Nov 12 at 2:00 pm ET